Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial — Thomas Vanassche (2021) | RDL Network
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial
Article 2021 en
Authors
TV
Thomas Vanassche
PV
Peter Verhamme
SA
Sonia S. Anand
Abstract
1 min read
Adding low-dose rivaroxaban to aspirin resulted in benefits irrespective of the number of concomitant drugs or comorbidities. Multiple comorbidities and/or polypharmacy should not dissuade the addition of rivaroxaban to aspirin in otherwise eligible patients.
Thomas Vanassche, Peter Verhamme, Darryl P. Leong, Deepak L. Bhatt, Olga Shestakovska, Aldo Maggioni, Keith A.A. Fox, Eva Muehlhofer, Stuart J. Connolly, Salim Yusuf, John W. Eikelboom, Jackie Bosch
Mukul Sharma, Robert G. Hart, Stuart J. Connolly, Jackie Bosch, Olga Shestakovska, Kelvin Kuan Huei Ng, Luciana Catanese, Katalin Keltai, Victor Aboyans, Marco Alings, Jong‐Won Ha, George Varigos, Andrew Tonkin, Martin O’Donnell, Deepak L. Bhatt, Keith A.A. Fox, Aldo Maggioni, Scott D. Berkowitz, Nancy Cook Bruns, Salim Yusuf, John W. Eikelboom
Discussion(0)
No comments yet. Be the first to comment.